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What Was Already Known About this Topic and What Does This Work Add? 
The HOME (Harmonising Outcome Measures for Eczema) initiative has 
recommended core outcome domains and corresponding instruments that should be 
measured and reported in all trials of atopic eczema treatments. The impact of these 
recommendations was not known with no formal quantification of their uptake in 
trials. The study provides quantitative results of the uptake of recommended 
domains and corresponding instruments. Assessment has shown uptake has 
increased since the recommendation, but that there is still room for improvement.  
 
Research Letter  
The Harmonising Outcome Measures for Eczema (HOME) initiative has 
recommended a Core Outcome Set (COS) for atopic eczema clinical trials1. 
Adherence to this COS in future clinical trials of atopic eczema treatments will 
ensure outcomes are measured and reported consistently, thus allowing direct 
comparison and minimising bias2. The COS consists of domains (what should be 
measured) and instruments (how to measure it). In 2011 four core domains were 
agreed i) clinician-reported signs, ii) patient-reported symptoms, iii) dermatology-
specific quality of life (QoL) and iv) long-term control. EASI (Eczema Area and 
Severity Index, 2013) and POEM (Patient Oriented Eczema Measure, 2015) are the 
agreed instruments for signs and symptoms, respectively.  EASI combines the 
severity of the signs of eczema with the extent to which the body is affected3, and 
POEM is a seven-item questionnaire that captures the frequency of symptoms of 
eczema experienced over the previous week4. Using the WHO International Clinical 
Trials Registry Platform (ICTRP), a network of international clinical trials registers, 
we sought to quantify uptake of the HOME core outcomes in clinical trials over time. 
 
We included Phase III/IV treatment trials involving adults and/or children with atopic 
eczema registered within the WHO ICTRP between 24th January 2005 and 16th June 
2018. We excluded trials of interventions for primary eczema prevention and those 
that never commenced. We independently screened records for eligibility (CMcW 
and RV) and extracted data for signs, symptoms and skin-related QoL domains.  The 
long-term control domain was excluded because the HOME group had not defined 
this domain when we conducted our review. At the instrument level, EASI and POEM 
uptake was explored for clinician-reported signs and patient-reported symptoms, 
respectively. To assess change over time, trials were ordered by registration date 
and divided into five-year blocks, from which the percentage of trials reporting the 




Figure 1: Uptake of the HOME COS and individual domains (left) , and uptake of the HOME COS Outcome 
Measurement Instruments (right) 
 
 
177/241 eligible records were identified.  The included trials were registered in ten 
different trial registries, with 122/177 registered on ClinicalTrials.gov (69%). 120/177 
were registered prospectively (68%), 122/177 were industry-sponsored (69%) and 
111/177 were multi-centre trials (63%). The median sample size was 150 
(interquartile range 53-375). Trial participants comprised adults only (54/177; 31%), 
children only (72/177; 41%) and adults and children (51/177; 29%). The average 
overall collection of the COS (signs, symptoms and QoL) from 2005-2018 was 25% 
(45/177), increasing to 33% (4/12) in the year 2018. EASI and POEM collection also 
increased, in 2018 they were used in 92% (11/12) and 17% (2/12) of trials 
respectively (see figure 1).    
 
We found an increase in the proportion of atopic eczema treatment trials that 
included the recommended domains of signs, symptoms and dermatology-specific 
QoL, with uptake of the specific instruments of EASI and POEM. The overall 
increase in patient-reported symptoms and QoL could reflect increasing recognition 
of the importance of patient-reported outcomes in trials. Uptake of the QoL domain 
has remained low, it is worth noting that QoL instruments were recommended in 
20191, after our data collection had taken place.   
 
The inclusion of core domains in atopic eczema trials was already increasing at the 
time of the initial HOME domain recommendations in 2012. This may be because the 
eDelphi consensus on domains published in 2010 encouraged their inclusion even 
before the HOME consensus publication in 20125. 
 
Whilst uptake of a COS and associated instruments is a step forward, it is not, by 
itself, sufficient. Unless domains and instruments are measured at comparable time 
points and data presented in a suitable format for meta-analysis, difficulties in 
synthesising data will remain. HOME have begun to address this by recommending 
that all trials, for each primary outcome, report mean and standard deviation at 
baseline and end of treatment as a minimum6.   
 
In summary, we present a systematic assessment of the uptake of the HOME COS. 
The published COS and instruments, agreed by a consensus methodology 
encompassing all stakeholders in the decision-making process, appears to have 
supported adoption of the HOME recommendations by the research community. 
Other COS development groups should be encouraged by these findings. Further 
work is needed by funders, journal editors and systematic reviewers to promote and 
mandate use of COSs. 
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